Keros Therapeutics, Inc. (KROS) has 7 SEC Form 4 insider filings on record in the last 90 days. That includes 2 insider purchases totalling $21K, and 4 sales totalling $101K. Most recent filing: Aug. 20, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Aug. 20, 2026 filed Aug. 18, 2026 | Lerner Lorena Raquel Chief Scientific Officer | −$36,715 | 3,568 | −11% | No | |
|
|
||||||
| Aug. 20, 2026 filed Aug. 18, 2026 | Tanini Annita Corp. Controller & VP, Finance | −$12,595 | 1,224 | −3% | No | |
|
|
||||||
| Aug. 20, 2026 filed Aug. 18, 2026 | Cho Esther Chief Legal Officer | −$46,151 | 4,485 | −11% | No | |
|
|
||||||
| Aug. 20, 2026 filed Aug. 18, 2026 | Newton Charles W. Director | −$5,675 | 551 | −4% | Yes | |
|
|
||||||
| Aug. 19, 2026 filed Aug. 17, 2026 | BIENAIME JEAN JACQUES Director | +$10,270 | 1,000 | +5% | Yes | |
|
|
||||||
Showing the 5 most recent of 7 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free